Company Overview and News
MELBOURNE, Australia, Sept. 14, 2018 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a late stage clinical biopharmaceutical company developing first-in-class novel biologic therapies to treat back-of-the-eye diseases, announced today that new clinical data analysis from its completed Phase 1/2a trial of intravitreally injected OPT-302 with and without Lucentis® (ranibizumab) for the treatment of wet AMD was presented at the Retina Society 2018 Annual meeting in San Francisco, CA.
MELBOURNE, Australia, Sept. 05, 2018 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a late stage biopharmaceutical company developing novel biologic therapies to treat back-of-the eye diseases, today announced that the independent Data and Safety Monitoring Board (DSMB) for the Company’s ongoing Phase 2b study of OPT-302 in wet age-related macular degeneration (wet AMD) patients has completed the first, pre-planned safety review and has unanimously recommended that the trial continue without modification.
Opthea Ltd (ASX:OPT) (FRA:UKJ) (OTCMKTS:CKDXY), a Victorian company focused on commercialising eye therapeutics, plans to enrol and dose patients in two Phase 2-stage clinical trials in the next 12 months.
MELBOURNE, Australia, July 30, 2018 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a late stage biopharmaceutical company developing novel biologic therapies to treat back-of-the eye diseases, has successfully dosed the first patient in the Phase 2a randomised, controlled clinical trial evaluating the safety and efficacy of OPT-302 in patients with persistent center-involved diabetic macular edema (DME).
MELBOURNE, Australia, July 26, 2018 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a late stage biopharmaceutical company developing novel biologic therapies to treat back-of-the eye diseases, announced today that its Phase 1b trial for Diabetic Macular Edema (DME) has successfully met its primary objective of demonstrating acceptable safety and tolerability. The study is investigating dose escalation of OPT-302, the Company’s lead molecule, administered in combination with aflibercept (Eylea®) on a monthly basis for three months by ocular injection in patients with persistent central-involved DME despite prior sub-optimal responses to standard of care anti-VEGF-A therapy.
MELBOURNE, Australia, July 02, 2018 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a late stage biopharmaceutical company developing novel biologic therapies to treat back-of-the eye diseases, is pleased to announce it has reached the mid-way point of patient recruitment for its Phase 2b clinical trial of OPT-302 in wet age-related macular degeneration (wet AMD) patients. The Company remains on-track to report primary data from the study in early 2020.
MELBOURNE, Australia, March 27, 2018 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a developer of novel biologic therapies for the treatment of eye diseases, has dosed the first patients in Europe and Israel in the Company’s ongoing Phase 2b trial of OPT-302 for wet age-related macular degeneration (AMD). The study, which is a randomised, controlled clinical trial of OPT-302, a novel VEGF-C/D ‘Trap’ therapy, in combination with ranibizumab (Lucentis®) for wet AMD commenced dosing at clinical sites across the U.
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Silicon Investor Message Boards
This table lists all message boards related to ASX:OPT / OPTHEA LIMITED on message board site Silicon Investor.